{"id":"W2146161922","doi":"10.1056/nejmoa043116","title":"Capecitabine as Adjuvant Treatment for Stage III Colon Cancer","year":2005,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1247,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Capecitabine; Medicine; Fluorouracil; Hazard ratio; Internal medicine; Colorectal cancer; Regimen; Clinical endpoint; Bolus (digestion); Adverse effect; Gastroenterology; Oncology; Adjuvant; Surgery; Confidence interval; Chemotherapy; Cancer; Randomized controlled trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03438742929994011,"score_gpt":0.3506999515904616,"score_spread":0.3163125222905215,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}